Akebia Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Waltham, MA
AKBA chart
What traders are saying about $AKBA
Latest postsAkebia Therapeutics, Inc. news
- Akebia Therapeutics and U.S. Renal Care Present Positive VOICE Trial Data for Vafseo at ASN Kidney Week 2026
Quiver Quantitative ·
- Akebia Therapeutics, Inc. (AKBA) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
Yahoo Finance ·
- Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Sell"
MarketBeat ·
- Akebia Therapeutics receives Nasdaq notice for minimum bid price deficiency
Investing.com ·
- Akebia Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
TradingView ·
- Form 8K Akebia Therapeutics Inc For: 23 October By Investing.com
Investing.com UK ·
- After 30 business days below $1, Akebia Therapeutics (Nasdaq: AKBA) gets a compliance deadline.
Stock Titan ·
- Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4
Moomoo ·
- Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
Yahoo Finance ·
- Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
Yahoo Finance ·
- SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
Yahoo Finance ·
Akebia Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M |
| Net income | -$5.3M | -$69.4M | -$51.9M | -$94.2M |
| Diluted EPS | $-0.02 | $-0.33 | $-0.28 | $-0.52 |
| Total assets (year end) | $376.6M | $220.7M | $241.7M | $356.1M |
| Cash and equivalents (year end) | $184.8M | $51.9M | $42.9M | $90.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Akebia Therapeutics, Inc.
- Ticker
- AKBA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1517022
Frequently asked questions
What exchange is Akebia Therapeutics, Inc. listed on?
Akebia Therapeutics, Inc. trades on the Nasdaq under the ticker symbol AKBA.
What industry is Akebia Therapeutics, Inc. in?
Akebia Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Akebia Therapeutics, Inc. headquartered?
Akebia Therapeutics, Inc.'s business address on file with the SEC is in Waltham, MA.
When does Akebia Therapeutics, Inc.'s fiscal year end?
Akebia Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Akebia Therapeutics, Inc. report?
Akebia Therapeutics, Inc. reported $236.2M in revenue for calendar year 2025, according to its SEC filings.